ReviewWorld journal of gastroenterology2024
Treat to target in Crohn's disease: A practical guide for clinicians.
Review in World journal of gastroenterology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- Dose-dependent efficacy and safety of Filgotinib in moderate to severe Crohn's disease: a grade-assessed systematic review and meta-analysis of randomized controlled trials.European journal of clinical pharmacology · 2025Pooled it
- A patient-reported outcome measure comprising the stool frequency and abdominal pain items from the Crohn's Disease Activity Index: psychometric evaluation in adults with Crohn's disease.Journal of patient-reported outcomes · 2025Trial
- Visual theranostic oral nanozymes for IBD from principles to preclinical design.Bioactive materials · 2026Review
- Evaluating sonographic response and remission in inflammatory bowel disease: aligning intestinal ultrasound assessment with STRIDE-II timelines.Journal of Crohn's & colitis · 2026Review
- Efficacy and safety of dual biologics or combination therapy with JAK inhibitors in refractory inflammatory bowel disease: a retrospective single-center real-world study from China.BMC gastroenterology · 2026Article
- The CT-based attenuation index of peri-bowel adipose tissue can predict disease progression in inflammatory bowel disease patients.European radiology · 2026Article
- Integrating Intestinal Ultrasound in the Personalized Management of IBD.Journal of personalized medicine · 2026Review
- Integrated Assessment of Intestinal Barrier Function and Microscopic Inflammation Using Confocal Laser Endomicroscopy for Relapse Prediction in Ulcerative Colitis.United European gastroenterology journal · 2026Article
- Comparative Effectiveness and Safety of Risankizumab vs Ustekinumab in Crohn's Disease: A Real-World Retrospective Cohort Study from Taiwan.Journal of inflammation research · 2026Article
- Examining attitudes to intestinal ultrasound in inflammatory bowel disease: a national survey of Australian gastroenterologists.Therapeutic advances in gastroenterology · 2026Article
- Neutrophil count and platelet-lymphocyte ratio as simple predictors of ustekinumab response in patients with Crohn's disease: a retrospective multicenter study.Frontiers in immunology · 2026Article
- Shared inflammatory architecture and therapeutic tensions between psoriasis and Crohn's disease.Frontiers in immunology · 2026Review
- Filgotinib in Moderate-to-Severe Crohn's Disease: A Network Meta-Analysis of Efficacy and Adverse Events.Healthcare (Basel, Switzerland) · 2025Review
- IFX Is Associated with Higher Rates of 2-Year Mucosal Healing in Biologic-Naïve CD Patients Compared to UST.Digestive diseases and sciences · 2025Article
- Beyond Fixed Thresholds: Cluster-Derived MRI Boundaries Improve Assessment of Crohn's Disease Activity.Journal of clinical medicine · 2025Article
- Imaging in perianal fistulising Crohn's disease: A practical guide for the gastroenterologist.World journal of gastroenterology · 2025Review
- Long-Term Clinical and Endoscopic Outcomes of Crohn's Disease Following Liver Transplantation: A Multicenter Cohort Study.Biomedicines · 2025Article
- Clinical Predictive Factors for the Development of Short Bowel Syndrome in a Cohort of Patients with Crohn's Disease: A Prospective Study.Journal of clinical medicine · 2025Article
- A Guide to the Patient-Centric Use of Vedolizumab for Crohn's Disease.Inflammatory bowel diseases · 2025Review
- Evaluating luminal and post-operative Crohn's disease activity on magnetic resonance enterography: A review of radiological disease activity scores.World journal of gastroenterology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A treat-to-target (T2T) approach applies the principles of early intervention and tight disease control to optimise long-term outcomes in Crohn's disease. The Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE)-II guidelines specify short, intermediate, and long-term treatment goals, documenting specific treatment targets to be achieved at each of these timepoints. Scheduled appraisal of Crohn's disease activity against pre-defined treatment targets at these timepoints remains central to determining whether current therapy should be continued or modified. Consensus treatment targets in Crohn's disease comprise combination clinical and patient-reported outcome remission, in conjunction with biomarker normalisation and endoscopic healing. Although the STRIDE-II guidelines endorse the pursuit of endoscopic healing, clinicians must consider that this may not always be appropriate, acceptable, or achievable in all patients. This underscores the need to engage patients at the outset in an effort to personalise care and individualise treatment targets. The use of non-invasive biomarkers such as faecal calprotectin in conjunction with cross-sectional imaging techniques, particularly intestinal ultrasound, holds great promise; as do emerging treatment targets such as transmural healing. Two randomised clinical trials, namely, CALM and STARDUST, have evaluated the efficacy of a T2T approach in achieving endoscopic endpoints in patients with Crohn's disease. Findings from these studies reflect that patient subgroups and Crohn's disease characteristics likely to benefit most from a T2T approach, remain to be clarified. Moreover, outside of clinical trials, data pertaining to the real-world effectiveness of a T2T approach remains scare, highlighting the need for pragmatic real-world studies. Despite the obvious promise of a T2T approach, a lack of guidance to support its integration into real-world clinical practice has the potential to limit its uptake. This highlights the need to describe strategies, processes, and models of care capable of supporting the integration and execution of a T2T approach in real-world clinical practice. Hence, this review seeks to examine the current and emerging literature to provide clinicians with practical guidance on how to incorporate the principles of T2T into routine clinical practice for the management of Crohn's disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.